Zhi Ping Xu - Search Results

Year	Number of Results
2006	3
2007	5
2008	4
2009	5
2010	6
2011	9
2012	9
2013	9
2014	13
2015	14
2016	7
2017	19
2018	25
2019	22
2020	15
2021	20
2022	19
2023	14
2024	6

1

PD-L1 Distribution and Perspective for Cancer Immunotherapy-Blockade, Knockdown, or Inhibition.

Wu Y, Chen W, Xu ZP, Gu W. Wu Y, et al. Among authors: xu zp. Front Immunol. 2019 Aug 27;10:2022. doi: 10.3389/fimmu.2019.02022. eCollection 2019. Front Immunol. 2019. PMID: 31507611 Free PMC article. Review.

2

A dendritic/tumor fusion cell vaccine enhances efficacy of nanobody-based CAR-T cells against solid tumor.

Sun S, Ding Z, Gao L, Hammock BD, Huang X, Xu ZP, Wang X, Cheng Q, Mo F, Shi W, Xie S, Liu A, Li H, Yang X, Lu X. Sun S, et al. Among authors: xu zp. Theranostics. 2023 Sep 18;13(14):5099-5113. doi: 10.7150/thno.84946. eCollection 2023. Theranostics. 2023. PMID: 37771772 Free PMC article.

3

Nanobody-based bispecific T-cell engager (Nb-BiTE): a new platform for enhanced T-cell immunotherapy.

Yang XM, Lin XD, Shi W, Xie SX, Huang XN, Yin SH, Jiang XB, Hammock BD, Xu ZP, Lu XL. Yang XM, et al. Among authors: xu zp. Signal Transduct Target Ther. 2023 Sep 4;8(1):328. doi: 10.1038/s41392-023-01523-3. Signal Transduct Target Ther. 2023. PMID: 37661200 Free PMC article. No abstract available.

4

Trends in versatile 2D (sheet/paper-like) nanomaterials for biomedical applications.

Kankala RK, Xu ZP. Kankala RK, et al. Among authors: xu zp. Adv Drug Deliv Rev. 2023 Jan;192:114645. doi: 10.1016/j.addr.2022.114645. Epub 2022 Dec 5. Adv Drug Deliv Rev. 2023. PMID: 36470412 No abstract available.

5

Artificial cells for the treatment of liver diseases.

Zou D, Wang H, Liu X, Xu ZP, Roberts MS, Zhao CX. Zou D, et al. Among authors: xu zp. Acta Biomater. 2021 Aug;130:98-114. doi: 10.1016/j.actbio.2021.06.012. Epub 2021 Jun 12. Acta Biomater. 2021. PMID: 34126265 Review.

6

Two-dimensional nanomaterials for tumor microenvironment modulation and anticancer therapy.

Wu M, Niu X, Zhang R, Ping Xu Z. Wu M, et al. Among authors: ping xu z. Adv Drug Deliv Rev. 2022 Aug;187:114360. doi: 10.1016/j.addr.2022.114360. Epub 2022 May 28. Adv Drug Deliv Rev. 2022. PMID: 35636568 Review.

7

Nanotechnology in the management of cervical cancer.

Chen J, Gu W, Yang L, Chen C, Shao R, Xu K, Xu ZP. Chen J, et al. Among authors: xu zp. Rev Med Virol. 2015 Mar;25 Suppl 1:72-83. doi: 10.1002/rmv.1825. Rev Med Virol. 2015. PMID: 25752817 Review.

8

Dynamic nano-assemblies based on two-dimensional inorganic nanoparticles: Construction and preclinical demonstration.

Sun L, Wang J, Li L, Xu ZP. Sun L, et al. Among authors: xu zp. Adv Drug Deliv Rev. 2022 Jan;180:114031. doi: 10.1016/j.addr.2021.114031. Epub 2021 Nov 1. Adv Drug Deliv Rev. 2022. PMID: 34736985 Review.

9

Penetration of nanoparticles into human skin.

Liang XW, Xu ZP, Grice J, Zvyagin AV, Roberts MS, Liu X. Liang XW, et al. Among authors: xu zp. Curr Pharm Des. 2013;19(35):6353-66. doi: 10.2174/1381612811319350011. Curr Pharm Des. 2013. PMID: 23469998 Review.

10

Nano- and micro-materials in the treatment of internal bleeding and uncontrolled hemorrhage.

Gaston E, Fraser JF, Xu ZP, Ta HT. Gaston E, et al. Among authors: xu zp. Nanomedicine. 2018 Feb;14(2):507-519. doi: 10.1016/j.nano.2017.11.007. Epub 2017 Nov 21. Nanomedicine. 2018. PMID: 29162534 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

186 results

Results by year

Search Page

Filters

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

Search Results

186 results

Results by year